Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
IPO Year: 1998
Exchange: NASDAQ
Website: rockwellmed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | $5.00 | Buy | Rodman & Renshaw |
| 1/18/2022 | $5.00 → $3.00 | Buy | HC Wainwright & Co. |
| 9/7/2021 | $5.50 → $5.00 | Buy | HC Wainwright & Co. |
Partnership is expected to generate upwards of $10 million in net sales for the Company in 2025, with incremental price increases each subsequent year and an effective term of up to five years Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a product purchase agreement (the "Agreement") with the world's leading provider of dialysis products and services ("the Customer"). Rockwell Medical is the leading supplier of liquid bicarbonate in the United States and the only organization that cu
Incumbent Board has Destroyed Stockholder Value and Imperiled AIM's Future through Breaches of Fiduciary Duty and Bad Faith Actions Stock Price has Declined by More than 99%, Clinical Strategy has Failed and AIM is on the Brink of Insolvency Act Now to Save AIM Before it is Too Late – The Kellner Group Can Turn AIM Around and Finally Start Creating Value for Stockholders Vote "FOR" All Four Kellner Group Nominees for Urgently Needed Change Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Dear AIM Stockholders: Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees,
Vote "FOR" All Four Kellner Group Nominees for Urgently Needed Change Incumbent Board has Destroyed Stockholder Value and Imperiled AIM's Future through Breaches of Fiduciary Duty and Bad Faith Actions Stock Price has Declined by More than 99%, Clinical Strategy has Failed and AIM is on the Brink of Insolvency Act Now to Save AIM Before it is Too Late – The Kellner Group Can Turn AIM Around and Finally Start Creating Value for Stockholders NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Dear AIM Stockholders: Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Pau
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Jesse Neri was promoted to Chief Financial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212901260/en/Jesse Neri - Chief Financial Officer at Rockwell Medical, Inc. (Photo: Business Wire) "Over the past year, Jesse has been instrumental in strengthening Rockwell's financial infrastructure, reshaping our financial strategy, and developing a stronger public company financial organization and pre
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has partnered with HydroCare, a leading provider of state-of-the-art dialysis water treatment systems to healthcare facilities globally, to purchase and install the Company's dry acid concentrate mix system in dialysis water rooms. Rockwell anticipates that with these new mixer installations through HydroCare, the Company will also generate new sales related to its dry acid hemodialysis concentrates. Rockwell Medical's DAMX45 dry acid concentrate mix syste
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a distribution agreement with Nephro Group Dialysis Centers ("Nephro Group"), the largest dialysis provider in the Philippines. Under the terms of the agreement, Rockwell Medical will be the exclusive supplier of all dry hemodialysis concentrates products, including its CitraPure® Acid and RenalPure® Bicarbonate, to Nephro Group. "Nephro Group was founded in 1995 with the vision to provide all Filipinos high quality, accessible, and affordab
Reports net product sales of $28.3 million for the third quarter of 2024, an increase of 31% over net product sales for the same period in 2023. Net product sales for the third quarter of 2024 included a special large order of premium-priced products by our largest customer. Reports gross profit of $6.2 million for the third quarter of 2024, an increase of 183% over the same period in 2023. Achieves gross margin of 22% for the third quarter of 2024 compared to a gross margin of 9% for the same period in 2023. Generates $4.3 million in cash flow from operations for the third quarter of 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops
Due to the U.S. Securities and Exchange Commission (SEC) and its Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system being closed on Monday, November 11, 2024 in observance of Veteran's Day, the Company will release its financial and operational results for the Third Quarter 2024 on Tuesday, November 12, 2024 Press release will be issued at 6:00am ET followed by a live conference call and webcast at 8:00am ET Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has updated the date for its third quart
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2024 on Monday, November 11, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, November 11, 2024 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Result
Provides Customer with the only hemodialysis concentrates convenience pack in the dialysis marketplace to support its at-home and acute care patient populations Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced a product purchase agreement with the leading at-home and acute care dialysis provider in the United States (the "Customer"). Under the terms of the agreement, Rockwell Medical will supply the Customer with the Company's liquid acid RenalPure® and liquid bicarbonate SteriLyte®, both of which will be packaged in ei
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
3 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
3 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
144 - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
424B5 - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
10-Q - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
EFFECT - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
S-8 - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
S-3 - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
Reports net product sales of $28.3 million for the third quarter of 2024, an increase of 31% over net product sales for the same period in 2023. Net product sales for the third quarter of 2024 included a special large order of premium-priced products by our largest customer. Reports gross profit of $6.2 million for the third quarter of 2024, an increase of 183% over the same period in 2023. Achieves gross margin of 22% for the third quarter of 2024 compared to a gross margin of 9% for the same period in 2023. Generates $4.3 million in cash flow from operations for the third quarter of 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops
Due to the U.S. Securities and Exchange Commission (SEC) and its Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system being closed on Monday, November 11, 2024 in observance of Veteran's Day, the Company will release its financial and operational results for the Third Quarter 2024 on Tuesday, November 12, 2024 Press release will be issued at 6:00am ET followed by a live conference call and webcast at 8:00am ET Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has updated the date for its third quart
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2024 on Monday, November 11, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, November 11, 2024 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Result
Reports net sales of $25.8 million for the second quarter of 2024, an increase of 43% over the same period in 2023. Reports gross profit of $4.6 million for the second quarter of 2024, an increase of 341% over the same period in 2023. Achieves gross margin of 18% for the second quarter of 2024 compared to a gross margin of 6% for the same period in 2023. Generates $1.4 million in cash flow from operations for the second quarter of 2024. Expects net sales for 2024 to range between $95 million and $98 million, raising guidance for the second time this year. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, a
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, August 8, 2024 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Result
Reports record net sales of $22.7 million for the first quarter of 2024, an increase of 25% over net product sales and a 15% increase over net sales for the same period in 2023. Reports record gross profit of $3.1 million for the first quarter of 2024, an increase of 18% over the same period in 2023. Raises guidance for net sales, gross profit, and profitability on an adjusted EBITDA basis for the full-year 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three mo
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2024 on Tuesday, May 14, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Tuesday, May 14, 2024 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Fo
Reports record net sales for second year in a row, generating $83.6 million in 2023, an increase of 15% over 2022. Net sales for the fourth quarter of 2023 were $22.1 million, an increase of 14% over the same period in 2022. Reports record net product sales for second year in a row, generating $79.8 million in 2023, an increase of 15% over 2022. Net product sales for the fourth quarter of 2023 were $22.1 million, an increase of 22% over the same period in 2022. Reports record gross profit for the second year in a row, generating $8.7 million in 2023, an increase of 114% over 2022. Achieves profitability on an adjusted EBITDA basis in the fourth quarter of 2023, the first time in t
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2023 on Thursday, March 21, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, March 21, 2024 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.Rock
Defers principal payments of $8.0 million up to three years, reduces Rockwell's need for additional operating capital, and enhances the Company's cash balance Rockwell Medical provides preliminary projected fourth quarter and full-year 2023 financial results Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company amended its loan and security agreement with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"). Rockwell Medical and its wholly owned subsidiary, Rockwell Transportation, Inc., initially e
Rodman & Renshaw initiated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00
HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $3.00 from $5.00 previously
HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00 from $5.50 previously
HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.50 from $9.00 previously
Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti
Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"
WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive Officer, effective July 1, 2022. Dr. Strobeck will also join the Company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and Chief Executive Officer and as a member of the Company's Board of Directors effective June 30, 2022. "We are exci
WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive Officer, effective July 1, 2022. Dr. Strobeck will also join the Company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and Chief Executive Officer and as a member of the Company's Board of Directors effective June 30, 2022. "We are exci
WIXOM, Mich., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today announced the appointment of industry leader and renowned life science industry executive, Ms. Andrea Heslin Smiley, to its Board of Directors, effective December 11, 2020. Ms. Smiley currently serves as President and Chief Executive Officer of VMS BioMarketing and is a member of the Board of Directors of life science company, Assertio (formerly Zyla Life Sciences). “We are pleased to
SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
SC 13G - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
SC 13G - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
SC 13G - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)